Georgakis points out that omics work usually shows up in observational cohorts, and credits Novo for building it into trials and sharing the findings.
Recap by typeshit. Post by Marios Georgakis on X.
A new GLP-1 described as stronger than current options is being tested in trials, and researchers lay out what people should understand about it.
A SURPASS-4 analysis at ASN Kidney Week 2026 found rapid kidney decline in 5% on tirzepatide versus 13% on insulin glargine, with the biggest gains in high protein groups.
Among 208,970 matched adults with type 2 diabetes, GLP-1 starters had 0.15% new diagnoses versus 0.10% on DPP-4 drugs. Authors call it a signal needing confirmation.
Researchers used AI to identify fungal peptides that taste salty or boost saltiness, aimed at cutting sodium in food. A food science find rather than a drug story.
ANZCA points to a UK study of 47,000 patients finding GLP-1 users had 11 times the risk of regurgitation or aspiration under general anaesthetic.
The clinic cites current recommendations to stop GLP-1s two months before trying to conceive and not to use them while pregnant. Check with a doctor for your own case.
Loading…